• Microban® International – the global leader in antimicrobial additives and odor control solutions – has released a statement discrediting unwarranted claims about the safety and efficacy of antimicrobial technologies. This statement is intended to ensure that the public, consumers, and other stakeholders are equipped to make fully informed decisions, based on scientific reasoning. Making a clear distinction between public health and non-public health claims, Microban has explained the advantages of incorporating its antimicrobial additives into

  • Anion dysregulation is seen in numerous diseases, from cystic fibrosis and chronic pain, to autism and cancer. Researchers at the University of Dallas are investigating anion transport in vivo, developing novel tools to help analyze the effects of both normal and aberrant anion regulation at the molecular level, and are using INTEGRA’s PIPETBOY acu 2 to streamline their cell

  • June Medical is one of 48 organisations to be recognised for their excellence in innovation in this year’s Queen’s Awards for Enterprise. Now in its 55th year, the Queen’s Awards for Enterprise are the most prestigious business awards in the country – rewarding only the most outstanding achievements – with winning businesses able to use the esteemed

  • A report from the International Agency for Research on Cancer1 recently classified TiO2 as ‘possibly carcinogenic to humans’ by inhalation and similarly, the European Chemicals Agency2 recommended TiO2 be classified as a category 2 carcinogen (suspected of causing cancer). In contrast, antimicrobial technologies from Microban International are based on SilverShield®, the first patented antimicrobial solution

  • INTEGRA Biosciences’ VIAFLO electronic pipettes are helping denovoMATRIX in Dresden, Germany, to produce modular, biomimetic coatings for cell culture plasticware that can be tailored to recreate a large variety of conditions for testing adherent cell cultures. Chief Scientific Officer Dr Richard Wetzel explained: “We have developed a range of pre-coated cell culture plasticware – screenMATRIX and myMATRIX – and

  • UK-based regulatory consultancy company Mosaic Surgical has formed a partnership with Key2Compliance – a Swedish provider of customised business solutions in the life sciences arena – to overcome some of the challenges associated with the UK leaving the European Union. From May 2021, medical device manufacturers outside of the UK wishing to sell their products into

  • Three new bio-layer interferometry (BLI) systems: Octet® R2 with 2-channels, Octet® R4 with 4-channels and Octet® R8 with 8-channels Field upgradeable to the higher channel system, providing the flexibility to expand based on throughput needs and budget   The Life Science Group Sartorius today launched the new high-performance Octet® R series of systems, the latest improvement in the company’s

  • Following the creation of a successful distribution partnership with Medworks to supply the Galaxy range to urology and gynecology surgery markets across several states, JUNE Medical is now rapidly expanding the availability of this popular range by recruiting a direct sales network to supply other states and additional surgical specialties.   Medworks is already supplying the

  • Microban International and Everbrite have joined forces to develop CrobialCoat™, an innovative coating that combines Microban antimicrobial technology and Everbrite ProtectaClear® to provide invisible surface protection with visible cleanliness. CrobialCoat is a durable, clear and highly adhesive coating designed to provide long-lasting product protection from rust, salt damage, tarnish, corrosion and oxidation on most surfaces, with the added benefit of built-in Microban antimicrobial technology. Eric Blaeser, Director of Business Development at Microban, said: “We are proud to partner with Everbrite to bring this novel

  • INTEGRA Biosciences’ ASSIST PLUS pipetting robot and VOYAGER adjustable tip spacing pipettes are proving invaluable to scientists at Southmead Hospital in Bristol, helping the development of novel antibiotics against resistant strains of Gram-negative bacteria. Senior research scientist Adrianna Olejniczak explained: “Our laboratory performs minimum inhibitory concentration (MIC) testing of potential antibiotics as part of the European